Literature DB >> 20038960

Time course of late rectal toxicity after radiation therapy for prostate cancer.

K Odrazka1, M Dolezel, J Vanasek, M Vaculikova, M Zouhar, J Sefrova, P Paluska, M Vosmik, T Kohlova, I Kolarova, Z Macingova, P Navratil, M Brodak, P Prosvic.   

Abstract

Rectum and bladder are the crucial organs at risk for curative radiation therapy of localized prostate cancer. We analyzed the incidence, profile and time course of late rectal radiation toxicity. A total of 320 patients with T1-3 prostate cancer were treated with three-dimensional conformal radiation therapy (3D-CRT). The prescription dose was 70 Gy for T1 and T2 patients (n=230) and 74 Gy for patients with locally advanced T3 tumors (n=90). Late rectal toxicity was graded according to the Fox Chase modification of the Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force (LENT) criteria. The median follow-up time was 6.2 years (range 0.2-10.7 years). At 5 years, the risk for the development of grade 2 and 3 rectal toxicities was 15.6 and 7.0%, respectively. All new cases of grade 2 and 3 rectal toxicities were observed within 5 years after treatment. Prevalence of grade 2 and 3 rectal symptoms showed fluctuation with maximum at 1.5 years and the minor peak at 4.5 years. Toxicity profile changed significantly over time. The proportion of rectal bleeding within grade 2 and 3 toxicity decreased from 85% at 1.5 years to 46% at 4.5 years. Conversely, the proportion of fecal incontinence among grade 2 and 3 rectal symptoms gradually increased (0% at 1.5 years vs 27% at 4.5 years). Late rectal radiation toxicity represents a dynamic process. Rectal bleeding decreases and fecal incontinence increases over time.

Entities:  

Mesh:

Year:  2009        PMID: 20038960     DOI: 10.1038/pcan.2009.56

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  5 in total

1.  Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.

Authors:  James B Yu; Laura D Cramer; Jeph Herrin; Pamela R Soulos; Arnold L Potosky; Cary P Gross
Journal:  J Clin Oncol       Date:  2014-03-10       Impact factor: 44.544

2.  Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal-Prostate Interface and Spare the Rectum: A Case Report.

Authors:  Dylan Conroy; Kelly Becht; Matthew Forsthoefel; Abigail N Pepin; Siyuan Lei; Abdul Rashid; Brian Timothy Collins; Jonathan W Lischalk; Simeng Suy; Nima Aghdam; Ryan Andrew Hankins; Sean P Collins
Journal:  Front Oncol       Date:  2021-01-07       Impact factor: 6.244

3.  Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel.

Authors:  Palak Kundu; Eric Y Lin; Stephanie M Yoon; Neil R Parikh; Dan Ruan; Amar U Kishan; Alan Lee; Michael L Steinberg; Albert J Chang
Journal:  Front Oncol       Date:  2022-03-08       Impact factor: 6.244

4.  Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer.

Authors:  Aurore Goineau; Virginie Marchand; Jérome Rigaud; Sylvain Bourdin; Emmanuel Rio; Loic Campion; Angélique Bonnaud-Antignac; Marc-André Mahé; Stéphane Supiot
Journal:  Radiat Oncol       Date:  2013-03-06       Impact factor: 3.481

5.  Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis.

Authors:  Jörg Tamihardja; Max Schortmann; Ingulf Lawrenz; Stefan Weick; Klaus Bratengeier; Michael Flentje; Matthias Guckenberger; Bülent Polat
Journal:  Strahlenther Onkol       Date:  2020-08-24       Impact factor: 3.621

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.